Aurobindo Pharma hits lifetime high as analysts make bull case on growth

Q: How long will it take to read this news story?

The story "Aurobindo Pharma hits lifetime high as analysts make bull case on growth" has 806 words across 31 sentences, which will take approximately 4 - 7 minutes for the average person to read.

Q: Which news outlet covered this story?

The story "Aurobindo Pharma hits lifetime high as analysts make bull case on growth" was covered 7 hours ago by Business Standard, a news publisher based in India.

Q: How trustworthy is 'Business Standard' news outlet?

Business Standard is a fully independent (privately-owned) news outlet established in 1975 that covers mostly business and finance news. The outlet is headquartered in India and publishes an average of 289 news stories per day. It's most recent story was published 3 hours ago.

Q: What do people currently think of this news story?

The sentiment for this story is currently Neutral, indicating that people are not responding positively or negatively to this news.

Q: How do I report this news for inaccuracy?

You can report an inaccurate news publication to us via our contact page. Please also include the news #ID number and the URL to this story.<ul><li>News ID: #22062554</li><li>URL: https://beamstart.com/news/aurobindo-pharma-hits-lifetime-high-17235440995041</li></ul>

Business Standard Logo Business Standard 7h ago

Aurobindo Pharma hits lifetime high as analysts make bull case on growth - Business Standard

Quick Summary:

Shares of Aurobindo Pharmaceuticals soared as much as 4.96 per cent, hitting their all time high at Rs 1532.

Shares of Aurobindo Pharmaceuticals soared as much as 4.96 per cent, hitting their all time high at Rs 1,532.85 per share on the BSE in Tuesday’s intraday trade.

Analysts at JM Financial believe that the company is making heavy investments in high return areas, including PenG and its derivatives, biosimilars, biologic contract development and manufacturing organisations (CDMO), specialty oncology, and complex injectables.